Stockscreener 앱 받기
12.57
2.36%
0.29
시간 외 거래:
12.53
-0.04
-0.32%
전일 마감가:
$12.28
열려 있는:
$12.29
하루 거래량:
279.07K
Relative Volume:
1.28
시가총액:
$327.47M
수익:
$31.38M
순이익/손실:
$-6.69M
주가수익비율:
-52.38
EPS:
-0.24
순현금흐름:
$-1.84M
1주 성능:
+1.78%
1개월 성능:
+20.52%
6개월 성능:
+280.91%
1년 성능:
+176.87%
1일 변동 폭
$12.17
$13.29
1주일 범위
$11.80
$13.29
52주 변동 폭
$3.03
$13.98
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
명칭
Eton Pharmaceuticals Inc
전화
(847) 787-7361
주소
21925 W. FIELD PARKWAY, DEER PARK, IL
ETON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
12.57 | 327.47M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-04 | 재개 | H.C. Wainwright | Buy |
| 2024-05-06 | 개시 | Craig Hallum | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-01-04 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-20 | 개시 | B. Riley FBR | Buy |
| 2019-06-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
Where are the Opportunities in (ETON) - Stock Traders Daily
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection) - The Manila Times
Eton Pharmaceuticals Acquires Rare Growth Disorder Drug Increlex, Expanding Pediatric Treatment Portfolio - StockTitan
Eton Pharmaceuticals, Inc. completed the acquisition of Increlex® from Ipsen Biopharmaceuticals, Inc. - Marketscreener.com
Eton Pharmaceuticals Announces Positive Results from Clinical Trial for PKU GOLIKE Protein Substitute - Defense World
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial - The Manila Times
Eton Pharma's PKU GOLIKE Clinical Trial Shows Breakthrough Results in Metabolic Control - StockTitan
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Up 32.6% in November - MarketBeat
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) top owners are retail investors with 58% stake, while 26% is held by institutions - Yahoo Finance
EcoR1 Capital, LLC Increases Stake in Eton Pharmaceuticals Inc. - GuruFocus.com
The Escalator: AstraZeneca, Eton Pharmaceuticals, AltruBio and more - MM+M Online
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer - GlobeNewswire
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Significant Increase in Short Interest - Defense World
Short Interest in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Expands By 7.6% - MarketBeat
Eton Pharmaceuticals Inc (ETON) Stock Price Down 5.4% on Dec 2 - GuruFocus.com
238,565 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Wasatch Advisors LP - MarketBeat
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Eton Pharmaceuticals Inc (ETON) Shares Up 4.24% on Nov 29 - GuruFocus.com
Eton PharmaSmall Cap That's Climbing - MSN
HC Wainwright Issues Pessimistic Forecast for ETON Earnings - MarketBeat
Eton acquires US rights to neonatal diabetes treatment from AMMTeK - Pharmaceutical Technology
HC Wainwright Reiterates "Buy" Rating for Eton Pharmaceuticals (NASDAQ:ETON) - MarketBeat
Eton Pharmaceuticals shares target lifted, holds buy on Amglidia acquisition By Investing.com - Investing.com UK
Eton Pharmaceuticals acquires U.S. rights to Amglidia from AMMTeK - Yahoo Finance
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) - GlobeNewswire
Eton Pharmaceuticals stock soars to all-time high of $11.12 By Investing.com - Investing.com Nigeria
Eton Pharmaceuticals stock soars to all-time high of $11.12 - Investing.com India
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Eton Pharmaceuticals Inc (ETON) Stock Price Up 4.34% on Nov 19 - GuruFocus.com
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Decline in Short Interest - MarketBeat
What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing' - Yahoo Finance
What is HC Wainwright's Estimate for ETON FY2024 Earnings? - MarketBeat
Eton Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
HC Wainwright Has Bearish Estimate for ETON Q1 Earnings - MarketBeat
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29% - Simply Wall St
Eton Pharma Stock Soars Over 140% In 2024More Upside Ahead? - RTTNews
Earnings call: Eton Pharmaceuticals reports growth and targets expansion - Investing.com India
Eton Pharmaceuticals (NASDAQ:ETON) Earns Buy Rating from HC Wainwright - MarketBeat
Analyst Expectations For Eton Pharmaceuticals's Future - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2024 Earnings Call Transcript - Insider Monkey
Eton Pharmaceuticals earnings beat by $0.03, revenue topped estimates - Investing.com UK
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Manila Times
Eton Pharmaceuticals' (NASDAQ:ETON) growing losses don't faze investors as the stock spikes 16% this past week - Simply Wall St
Eton Pharmaceuticals (NASDAQ:ETON) Secures New U.S. Patent for Proprietary Formulation of Hydrocortisone - Defense World
Eton Pharmaceuticals stock hits 52-week high at $9.13 By Investing.com - Investing.com South Africa
Eton Pharmaceuticals stock hits 52-week high at $9.13 - Investing.com
Eton Pharmaceuticals Inc (ETON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eton Pharmaceuticals Inc 주식 (ETON) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Oct 08 '24 |
Buy |
7.03 |
33,970 |
238,782 |
2,760,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 04 '24 |
Buy |
6.77 |
16,852 |
114,105 |
2,720,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 07 '24 |
Buy |
7.22 |
11,248 |
81,250 |
2,730,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 10 '24 |
Buy |
4.65 |
57,500 |
267,375 |
2,660,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 11 '24 |
Buy |
4.75 |
50,000 |
237,500 |
2,705,000 |
1.61%
1.65%
자본화:
|
볼륨(24시간):